Cencioni, Maria T.
Magliozzi, Roberta
Palmisano, Ilaria
Suwan, Keittisak
Mensi, Antonella
Fuentes-Font, Laura
Villar, Luisa M.
Fernández-Velasco, José I.
Migallón, Noelia Villarrubia
Costa-Frossard, Lucienne
Monreal, Enric
Ali, Rehiana
Romozzi, Marina
Mazarakis, Nicholas
Reynolds, Richard
Nicholas, Richard
Muraro, Paolo A.
Funding for this research was provided by:
Elena Pecci research project and the Fondazione Careggi Onlus
Red Española de Esclerosis Múltiple (RD16/0015/0001)
Plan Estatal I+D+I , ISCIII-Subdirección General de Evaluación and Fondo Europeo de Desarrollo Regional (Grant PI15/00513)
NIHR Biomedical Research Centre
Article History
Received: 26 October 2023
Accepted: 27 March 2024
First Online: 12 April 2024
Declarations
:
: The IRAS project ID 204872, REC reference 17/L0/0172 received approval from the Health Research Authority (HRA) and Health Care Research Wales (HCRW) ref 17/LO/0172/ according to the Declaration of Helsinki.The study project of investigation FIS PI15/00513 received approval from the ethics committee of University Hospital Ramon y Cajal according to the Declaration of Helsinki.All the human post-mortem tissues were collected with written informed consent forms via a prospective donor scheme with Ethical approval by the National Research Ethics Committee: IRAS project ID 246227, REC reference 18/WA/0238 according to the Declaration of Helsinki.
: MTC, RM, MR, AM, IP, KS, JIFV, NVM, LCF, EM, LMV, RA, LFF, NM and RR declare no competing interests.RN declares to have attended paid advisory boards with Roche, Biogen, and Novartis; to have received grants from the UK MS Society; and to act as Vice-chair of the National Institute of Clinical and Health Excellence HTA committee C. PAM reports no competing interest, and discloses consulting to Magenta Therapeutics, Jasper Therapeutics and Cellerys, none related to this study.